TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06311461

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: The acupuncturist will swab each point with alcohol. Needles will be inserted and retained for 30 minutes. Each needle will be rotated 3 times to stimulate the qi in the meridian; 10 minutes after insertion, 20 minutes after insertion, and just prior to removal at 30 minutes. Needles will be inserted using the standards of clean needle technique established by the Council of Colleges of Acupuncture and Oriental Medicine. One size acupuncture needle, 0.25 diameter × 40 mm length, will be used. All acupuncture needles are sterile, disposable, and made of surgical stainless steel with stainless steel wound heads. Sessions will be repeated twice weekly (with at least 2 off days in between) for 5 weeks (10 sessions).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention control
Description: Viewing non-pain related TED talk videos over 5 weeks approximately equal to 10 hours of treatment for the acupuncture group.
Study: NCT05943470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icodextrin Peritoneal Dialysis Solution
Description: alternative day use of icodextrin comparing with daily use of icodextrin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Icodextrin Peritoneal Dialysis Solution
Description: alternative day use of icodextrin comparing with daily use of icodextrin
Study: NCT05892250

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Description: Manual techniques and therapeutic exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy + Dynamic Humeral Centering exercises
Description: Manual techniques and therapeutic exercise and active dynamic humeral centering exercises
Study: NCT04485728

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Improvement Protocol Intervention for Hospitalized Antepartum Patients
Description: Patients are getting sleep hygiene education and a sleep hygiene kit.
Study: NCT05199922

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: M TAPA block
Description: Under aseptic conditions, a high frequency linear probe will be placed on the costochondral angle in the sagittal plane. Then the probe will be slightly angled deeply to visualize the lower view of the perichondrium. We will perform M-TAPA with totally 40 ml (20 ml for each side) of %0,25 bupivacaine.
Study: NCT03338764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM-1
Description: SM-1 3-drug combination product containing 50-mg diphenhydramine, 5-mg delayed-release zolpidem and 0.5-mg delayed-release lorazepam self-administered as needed to promote sleep

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical in appearance to SM-1 and has the same excipients, but no active ingredients or delayed-release coating materials, self-administered as needed to promote sleep
Study: NCT05947669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Infliximab is available in vials of 100 mg with pharmaceutical form of concentrate for solution for infusion. Participating sites will ensure availability of infliximab as part of the hospital's standard supply for use in the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisolone is available in vials of 40 mg. Methylprednisolone is a drug used for standard treatment first line for ir-colitis or diarrhoea CTCAE grade ≥ 3. Participating sites will ensure availability of methylprednisolone for use in the study as part of the hospitals standard supply.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone is available in vials of 40 mg. Methylprednisolone is a drug used for standard treatment first line for ir-colitis or diarrhoea CTCAE grade ≥ 3. Participating sites will ensure availability of methylprednisolone for use in the study as part of the hospitals standard supply.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Prednisolone is available in tablets of 25 or 5 mg. Oral corticosteroids are internationally recommended as initial treatment for ir-colitis and ir-diarrhoea CTCAE grade 2 \[24-27\]. Participating sites will ensure availability of prednisolone for use in the study as part of the hospitals' standard supply.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone is available in tablets of 25 or 5 mg. Oral corticosteroids are internationally recommended as initial treatment for ir-colitis and ir-diarrhoea CTCAE grade 2 \[24-27\]. Participating sites will ensure availability of prednisolone for use in the study as part of the hospitals' standard supply.
Study: NCT05394285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag
Description: The first chemotherapy cycle (single center, open label, randomized controlled):~When platelets were \<50\*109/L, oral hetrombopag 7.5 mg/day was started. When the platelet count is \>100\*109/L, the administration is suspended.~2nd chemotherapy cycle (exploratory study): Prophylactic use (60 cases in the test group and the control group): oral hetrombopag 7.5 mg/day (initial dose) was started on d2 after chemotherapy for 14 days.

Intervention type: DRUG
Group type: OTHER
Intervention: Hetrombopag
Description: The first chemotherapy cycle (single center, open label, randomized controlled):~When platelets were \<50\*109/L, oral hetrombopag 7.5 mg/day was started. When the platelet count is \>100\*109/L, the administration is suspended.~2nd chemotherapy cycle (exploratory study): Prophylactic use (60 cases in the test group and the control group): oral hetrombopag 7.5 mg/day (initial dose) was started on d2 after chemotherapy for 14 days.

Intervention type: DRUG
Group type: OTHER
Intervention: rh-TPO
Description: The first chemotherapy cycle (single center, open label, randomized controlled):~Start using rh-TPO 15000 units/day (subcutaneous injection) when platelets are less than 50\*109/L. When the platelet count is more than 100\*109/L, the administration is suspended.~2nd chemotherapy cycle (exploratory study): Prophylactic use (60 cases in the test group and the control group): oral hetrombopag 7.5 mg/day (initial dose) was started on d2 after chemotherapy for 14 days.
Study: NCT02503163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KCT-0809 ophthalmic solution
Study: NCT04472884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: All participants will receive SOC services for MCH and PrEP that will include health education, clinical assessments, laboratory safety monitoring, STI (syphilis, gonorrhea, and chlamydia) screening and treatment (including expedited partner treatment for
Study: NCT05594602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-235
Description: Subjects will receive EDP-235 on Days 1 and 14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-235
Description: Subjects will receive EDP-235 on Days 1 and 23

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-235
Description: Subjects will receive EDP-235 on Days 1 and 8
Study: NCT06604832

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PrabotulinumtoxinA-Xvfs
Description: Each vial of prabotulinumtoxinA-xvfs contains 100 units of product, and it will be reconstituted with 5 mL of bacteriostatic saline solution. 20 units of this intervention will only be injected to the left side of subject faces - intramuscularly to the corrugator supercilii and intradermally to the forehead region.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PrabotulinumtoxinA-Xvfs
Description: Each vial of prabotulinumtoxinA-xvfs contains 100 units of product, and it will be reconstituted with 5 mL of bacteriostatic saline solution. 20 units of this intervention will only be injected to the left side of subject faces - intramuscularly to the corrugator supercilii and intradermally to the forehead region.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IncobotulinumtoxinA
Description: Each vial of incobotulinumtoxinA contains 100 units of product, and it will be reconstituted with 5 mL of bacteriostatic saline solution. 20 units of this intervention will only be injected to the right side of subject faces - intramuscularly to the corrugator supercilii and intradermally to the forehead region.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline solution (placebo)
Description: As a placebo treatment, saline solution will be injected on the right side of the glabellar lines and forehead region instead of an active neuromodulator. The saline solution has no therapeutic effect and is used as a control to compare the results against the active treatment.
Study: NCT06612723

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-intensity gait training
Description: Individuals will perform up to 40 minutes of walking practice during 60 minute sessions while targeting heart rates of at least 70% heart rate reserve.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high-intensity gait training
Description: Individuals will perform up to 40 minutes of walking practice during 60 minute sessions while targeting heart rates of at least 70% heart rate reserve.
Study: NCT05594602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Subjects will receive itraconazole QD Days 5-18

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: Subjects will receive carbamazepine BID Days 5-23 and Days 24-27
Study: NCT06612723

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity coaching
Description: Individuals will receive feedback on the minutes of walking activity performed on non-training days and provided coaching strategies to increase this metric.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity coaching
Description: Individuals will receive feedback on the minutes of walking activity performed on non-training days and provided coaching strategies to increase this metric.
Study: NCT06611579

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Tricuspid Valve Replacement
Description: Replacement of the tricuspid valve using a transcatheter approach
Study: NCT06611709

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham taping (non-elastic medical cloth tape)
Description: sham taping

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesiotaping: A standard 5-cm wide KinesioⓇ Tex Gold
Description: A standard 5-cm wide KinesioⓇ Tex Gold

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercises
Description: home-based exercises

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: exercises
Description: home-based exercises
Study: NCT04684563

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: huCART19-IL18
Description: autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: huCART19-IL18
Description: autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: huCART19-IL18
Description: autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: huCART19-IL18
Description: autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: huCART19-IL18
Description: autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)
Study: NCT05594602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinidine
Description: Subjects will receive quinidine BID Days 5-12
Study: NCT05251142

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric training
Description: Jumps in place. Some examples include multiple vertical jumps while reaching an overhead object, squat jump, pike jump, or tuck jump.~* Standing jumps. Examples include the single leg jump, maximal vertical jump ,standing long jump or lateral long jump.~* Multiple hops and jumps. Examples would include multiple long jumps or cone hops performed in succession, such as 5 hops in a row~* Box drills. Examples of these drills include box jumps ,repeated box jumps, and single leg box jumps.~* Depth jumps. Examples include stepping off the box and landing, stepping off the box and jumping vertically immediately after landing, or stepping off the box, landing, and sprinting.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General exercises
Description: Dumbbell Squat: 3 sets of 15 reps, Dumbbell Alternating Bench Press: 3 sets of 15 reps, Straight Arm Pulldowns: 3 sets of 15 reps, Dumbbell Front Raises: 3 sets of 15 reps, Reverse Flyes: 3 sets of 15 reps, Overhead Tricep Extensions: 3 sets of 15 reps, Dumbbell Bicep Curls: 3 sets of 15 reps, Jackknife Crunches: 3 sets of 20 reps, Oblique Crunches: 3 sets of 20 reps, External Rotation: 3 sets of 15 reps
Study: NCT05568953

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stamaril
Description: Stamaril is licensed by the Health Sciences Authority (HSA), Singapore. The vaccine are manufactured by Sanofi Pasteur and sourced from Sanofi Pasteur's local distributor.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stamaril
Description: Stamaril is licensed by the Health Sciences Authority (HSA), Singapore. The vaccine are manufactured by Sanofi Pasteur and sourced from Sanofi Pasteur's local distributor.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stamaril
Description: Stamaril is licensed by the Health Sciences Authority (HSA), Singapore. The vaccine are manufactured by Sanofi Pasteur and sourced from Sanofi Pasteur's local distributor.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Imojev
Description: Imojev is licensed by the Health Sciences Authority (HSA), Singapore. The vaccine are manufactured by Sanofi Pasteur and sourced from Sanofi Pasteur's local distributor.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Imojev
Description: Imojev is licensed by the Health Sciences Authority (HSA), Singapore. The vaccine are manufactured by Sanofi Pasteur and sourced from Sanofi Pasteur's local distributor.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ixiaro
Description: Ixiaro is licensed by the Health Sciences Authority (HSA), Singapore. The Ixiaro vaccines are manufactured by Valneva and sourced from local distributor, Aenon Pharmaceuticals SEA Pte Ltd.
Study: NCT06019559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-757 and K-833
Description: Both administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-757 and matching placebo to K-833
Description: Both Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo to K-757 and matching placebo to K-833
Description: Both administered orally
Study: NCT05674162

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unobserved
Description: Participants walk a distance of 40 meters wearing the sensors, unobserved by the researcher.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Observed
Description: Participants walk a distance of 40 meters wearing the sensors, observed by the researcher.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Unobserved & Measured
Description: Participants walk a distance of 40 meters wearing the sensors, unobserved by the researcher and aware of the gait measurement by the sensors.
Study: NCT04588129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB-102
Description: (N-Methyl amisulpride)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB-102
Description: (N-Methyl amisulpride)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB-102
Description: (N-Methyl amisulpride)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB-102
Description: (N-Methyl amisulpride)
Study: NCT05153876

Intervention type: OTHER
Intervention: Questionnaires
Description: Headache attack descriptions, Headache related disability descriptions, Questionnaires, MIDAS, MSQv2.1, SF36
Study: NCT06094946

Intervention type: DRUG
Intervention: Ropivacaine Hydrocloride
Description: 1 mg/ml

Intervention type: DRUG
Intervention: Ropivacaine Hydrocloride
Description: 1 mg/ml

Intervention type: DRUG
Intervention: Fentanyl Citrate
Description: 2.5 micrograms/ml

Intervention type: DRUG
Intervention: Fentanyl Citrate
Description: 2.5 micrograms/ml
Study: NCT04684563

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: huCART19-IL18
Description: autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: huCART19-IL18
Description: autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: huCART19-IL18
Description: autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: huCART19-IL18
Description: autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: huCART19-IL18
Description: autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: huCART19-IL18
Description: autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: huCART19-IL18
Description: autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: huCART19-IL18
Description: autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: huCART19-IL18
Description: autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: huCART19-IL18
Description: autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)
Study: NCT04445740

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: i♥rhythm project
Description: behavioral mobile health intervention, targeting parents of 5-8 year olds, designed to promote consistent behavioral rhythms in children through consistent bedtimes, light exposure, meal timing, and physical activity.
Study: NCT04684563

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: huCART19-IL18
Description: autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: huCART19-IL18
Description: autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)
Study: NCT05275933

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TCM intervention
Description: Lian Hua Qing Wen Capsules (LH) are provided in addition to Standard Care medications which include Symptomatic therapies include Paracetamol, antihistamines (eg. Cetirizine, loratadine or chlorpheniramine) and etc pro re nata (PRN) basis accordingly to the patient's condition.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intervention
Description: Placebo Capsules (PC) are provided in addition to Standard Care medications which include Symptomatic therapies include Paracetamol, antihistamines (eg. Cetirizine, loratadine or chlorpheniramine) and etc pro re nata (PRN) basis accordingly to the patient's condition.
Study: NCT06338943

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Echocardiography to diagnose HFpEF

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire to determine the presence of adverse pregnancy outcomes history
Study: NCT04610138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNM-ZnAg
Description: ZnAg liquid solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNM-ZnAg
Description: ZnAg liquid solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Water
Study: NCT06119165

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Environmental nudges
Description: Participants will view protein, frozen meal, and snack products with eco-labels applied. For each category, they will then be instructed to select 1 item from that category they wish most to purchase. Categories will be shown in random order. If a participant selects a product with a red eco-label, they will be shown a peer comparison message and will be given an opportunity to switch to a product with a yellow or green eco-label.
Study: NCT05098327

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone 30 mg
Description: pioglitazone 30 mg dose 1 tab daily will be given for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo pills containing cellulose 1 pill daily will be given for 12 weeks
Study: NCT05219968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYR-210
Description: LYR-210 drug matrix (mometasone furoate)

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham procedure control
Description: Sham procedure control

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Background Therapy
Description: Daily Saline Irrigation

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Background Therapy
Description: Daily Saline Irrigation
Study: NCT06337864

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PreKUnil® LNAA Medical Food for PKU
Description: PreKUnil® LNAA Medical Food for PKU is a commercially available active LNAA treatment product for PKU.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PreKUnil® LNAA Medical Food for PKU
Description: PreKUnil® LNAA Medical Food for PKU is a commercially available active LNAA treatment product for PKU.